It’s true, they can! In fact, one African Crested Porcupine really had the internet wound up with his adorable case. The little guy was speeding around so fast! Well, as fast as one could expect for a ...

I think Hims & Hers Health has achieved "escape velocity", with a 95%+ increase year-over-year in Q4 2024 and expected 56%-63% growth in 2025, net of GLP-1 issues. The market overreacted to HIMS ...

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded versions of Ozempic and Wegovy. This approach is in response to ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims ...

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an all-time high by late February – only to plunge by half in ...

Introduction: What Even Is Hims & Hers Health? In the pop culture of the investing community, Hims & Hers Health, Inc. (NYSE:HIMS) (Hims for short) has been described in all manner of ways ...

Hims & Hers Health, Inc. (HIMS) shares rallied 5.7% in the last trading session to close at $34.75. This move can be attributable to notable volume with a higher number of shares being traded than ...

Hims & Hers Health Inc. (NYSE:HIMS) Hims & Hers rallied by 5.72 percent on Friday to finish at $34.75 apiece as investors loaded up on its shares despite the lack of catalysts to boost investing ...

Hims & Hers Health (NYSE: HIMS) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach delivered some good news for the mail-order drugs stock. Citing third ...

A view of the Hims smartphone app. Photo: Getty Images Hims & Hers Health will shut down Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe ...